Literature DB >> 28814496

Cardiometabolic Features of Polycystic Ovary Syndrome: Role of Androgens.

Licy L Yanes Cardozo1,2,3,4, Damian G Romero5,6,4, Jane F Reckelhoff2,6,6,4.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder that affects reproductive-age women. Hyperandrogenemia is present in a significant fraction (~80%) of women with PCOS. Increased prevalence of cardiometabolic risk factors is frequently observed in PCOS women. The present review aims to highlight the key role of androgens in mediating the negative cardiometabolic profile observed in PCOS women.
Copyright © 2017 the American Physiological Society.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28814496      PMCID： PMC5625266          DOI： 10.1152/physiol.00030.2016

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN： 1548-9221


  124 in total

1.  The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist.

Authors:  Gina L C Yosten; Willis K Samson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-24       Impact factor: 3.619

2.  Endothelin B receptor contribution to peripheral microvascular function in women with polycystic ovary syndrome.

Authors:  Megan M Wenner; Hugh S Taylor; Nina S Stachenfeld
Journal:  J Physiol       Date:  2011-08-08       Impact factor: 5.182

3.  Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.

Authors:  Mei-Jou Chen; Wei-Shiung Yang; Jehn-Hsiahn Yang; Chi-Ling Chen; Hong-Nerng Ho; Yu-Shih Yang
Journal:  Hypertension       Date:  2007-03-26       Impact factor: 10.190

4.  Roles for the sympathetic nervous system, renal nerves, and CNS melanocortin-4 receptor in the elevated blood pressure in hyperandrogenemic female rats.

Authors:  Rodrigo Maranon; Roberta Lima; Frank T Spradley; Jussara M do Carmo; Howei Zhang; Andrew D Smith; Elizabeth Bui; R Lucas Thomas; Mohadetheh Moulana; John E Hall; Joey P Granger; Jane F Reckelhoff
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-02-18       Impact factor: 3.619

Review 5.  P-450 metabolites of arachidonic acid in the control of cardiovascular function.

Authors:  Richard J Roman
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

Review 6.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

7.  Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp.

Authors:  Nigel K Stepto; Samantha Cassar; Anju E Joham; Samantha K Hutchison; Cheryce L Harrison; Rebecca F Goldstein; Helena J Teede
Journal:  Hum Reprod       Date:  2013-01-12       Impact factor: 6.918

8.  Serum total renin is elevated in women with polycystic ovarian syndrome.

Authors:  T A Jaatinen; I Matinlauri; L Anttila; P Koskinen; R Erkkola; K Irjala
Journal:  Fertil Steril       Date:  1995-05       Impact factor: 7.329

9.  Obstructive sleep apnea predisposes to nonalcoholic Fatty liver disease in patients with polycystic ovary syndrome.

Authors:  Luciana Tock; Gláucia Carneiro; Sônia M Togeiro; Helena Hachul; Andrea Z Pereira; Sérgio Tufik; Maria T Zanella
Journal:  Endocr Pract       Date:  2014-03       Impact factor: 3.443

Review 10.  Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance.

Authors:  Thomas M Barber; George K Dimitriadis; Avgi Andreou; Stephen Franks
Journal:  Clin Med (Lond)       Date:  2015-12       Impact factor: 2.659
View more
  10 in total

1.  MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction.

Authors:  Maryam Syed; Jana P Ball; Keisa W Mathis; Michael E Hall; Michael J Ryan; Marc E Rothenberg; Licy L Yanes Cardozo; Damian G Romero
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-08-28       Impact factor: 4.310

Review 2.  Obesity and cardiovascular disease in women.

Authors:  Camila Manrique-Acevedo; Bhavana Chinnakotla; Jaume Padilla; Luis A Martinez-Lemus; David Gozal
Journal:  Int J Obes (Lond)       Date:  2020-02-17       Impact factor: 5.095

Review 3.  Associations Between Serum Magnesium Concentrations and Polycystic Ovary Syndrome Status: a Systematic Review and Meta-analysis.

Authors:  Maedeh Babapour; Hamed Mohammadi; Maryam Kazemi; Amir Hadi; Mahsa Rezazadegan; Gholamreza Askari
Journal:  Biol Trace Elem Res       Date:  2020-08-18       Impact factor: 3.738

4.  Androgens, the kidney, and COVID-19: an opportunity for translational research.

Authors:  Licy L Yanes Cardozo; Samar Rezq; Jacob E Pruett; Damian G Romero
Journal:  Am J Physiol Renal Physiol       Date:  2021-01-19

5.  The effects of probiotic and selenium co-supplementation on parameters of mental health, hormonal profiles, and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome.

Authors:  Mehri Jamilian; Shirin Mansury; Fereshteh Bahmani; Zahra Heidar; Elaheh Amirani; Zatollah Asemi
Journal:  J Ovarian Res       Date:  2018-09-14       Impact factor: 4.234

6.  SARS-CoV-2 Viral Entry Proteins in Hyperandrogenemic Female Mice: Implications for Women with PCOS and COVID-19.

Authors:  Alexandra M Huffman; Samar Rezq; Jelina Basnet; Licy L Yanes Cardozo; Damian G Romero
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

Review 7.  Research Progress on the Effect of Epilepsy and Antiseizure Medications on PCOS Through HPO Axis.

Authors:  Shuang Li; Linhai Zhang; Nian Wei; Zhenzhen Tai; Changyin Yu; Zucai Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-21       Impact factor: 5.555

8.  A Pilot Trial: Fish Oil and Metformin Effects on ApoB-Remnants and Triglycerides in Women With Polycystic Ovary Syndrome.

Authors:  Donna Vine; Ethan Proctor; Olivia Weaver; Mahua Ghosh; Katerina Maximova; Spencer Proctor
Journal:  J Endocr Soc       Date:  2021-06-19

9.  Long-Lasting Androgen-Induced Cardiometabolic Effects in Polycystic Ovary Syndrome.

Authors:  Edgar D Torres Fernandez; Kristen V Adams; Maryam Syed; Rodrigo O Maranon; Damian G Romero; Licy L Yanes Cardozo
Journal:  J Endocr Soc       Date:  2018-07-10

10.  Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome.

Authors:  Jacob E Pruett; Edgar D Torres Fernandez; Steven J Everman; Ruth M Vinson; Kacey Davenport; Madelyn K Logan; Stephanie A Ye; Damian G Romero; Licy L Yanes Cardozo
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.